In September, the telecommunications giant announced it was boosting its dividend by 1.25 cents a share to $0.69 per share, ...

The U.S. drugmaker submitted its sweetened bid, which matches Novo’s offer from Tuesday, valuing Metsera at $86.20 a share, ...

Pfizer (PFE) posted notable earnings growth, with net profit margins improving to 15.6%, a lift from the previous period’s 7%. Year-over-year, EPS growth soared 133.3%, marking a sharp reversal from ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. As a result, Vertex should be worth more than Pfizer by 2030.

Wall Street analysts forecast that Pfizer (PFE) will report quarterly earnings of $0.66 per share in its upcoming release, pointing to a year-over-year decline of 37.7%. It is anticipated that ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the ...

Jon Smith explains why investors can look across the pond for stocks with attractive dividend forecasts and shares a specific ...

In the latest close session, Pfizer (PFE) was down 1.09% at $24.50. This move lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow experienced a rise of 0.34%, and the technology-dominated ...